Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (20%) |
| No statute on record | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 65.9% | +8.6% |
| PAGANO, ALEXANDER R | 1 | 78.8% | +11.5% |
| CRAIGO, BAHAR ALAWI | 1 | 46.9% | +27.0% |
| CORNET, JEAN P | 1 | 42.0% | +47.8% |
| BELL, SARA ELIZABETH | 1 | 73.5% | +39.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17890130 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | CORNET, JEAN P | 77d overdue |
| 18421494 | IRON COMPLEX COMPOUNDS FOR THERAPUTIC USE | PAGANO, ALEXANDER R | 59d overdue |
| 17718052 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | BELL, SARA ELIZABETH | 36d overdue |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CRAIGO, BAHAR ALAWI | 7d |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1692 | 1 |
| 1699 | 1 |
| 1628 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294572 | IRON COMPLEX COMPOUNDS FOR SUBCUTANEOUS USE IN THERAPY OF IRON DEFICIENCY IN COMPANION ANIMALS | BERRY, LAYLA D | 1623 | DP | Non-Final OA | 83d | Pending | Feb 02, 2024 |
| 18421494 | IRON COMPLEX COMPOUNDS FOR THERAPUTIC USE | PAGANO, ALEXANDER R | 1692 | Other | Final Rejection | 59d overdue | Pending | Jan 24, 2024 |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CRAIGO, BAHAR ALAWI | 1699 | Other | Non-Final OA | 7d | Pending | Aug 07, 2023 |
| 17890130 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | CORNET, JEAN P | 1628 | Other | Non-Final OA | 77d overdue | Pending | Aug 17, 2022 |
| 17718052 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | BELL, SARA ELIZABETH | 1625 | Other | Non-Final OA | 36d overdue | Pending | Apr 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial